Asparaginase erwinia chrysanthemi (recombinant)- rywn
Details of the Drug
- Generic Name:
- Asparaginase erwinia chrysanthemi (recombinant)- rywn
- Drug Type:
- Asparagine specific enzyme
- How the Drug is Given:
Injection, for intramuscular use
- Names:
- Asparaginase erwinia chrysanthemi (recombinant)- rywn
- Rylaze™
Indications and Usage
Rylaze™ is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Side effects needing medical attention
The most common adverse reactions are abnormal liver test, nausea, musculoskeletal pain, fatigue, infection, headache, fever, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.